Suppr超能文献

肿瘤病灶糖酵解与肿瘤病灶增殖用于预测接受厄洛替尼治疗的晚期非小细胞肺癌患者的疗效和预后差异。

Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.

机构信息

Department for Nuclear Medicine, University Hospital of Cologne, Germany.

出版信息

Clin Nucl Med. 2012 Nov;37(11):1058-64. doi: 10.1097/RLU.0b013e3182639747.

Abstract

PURPOSE

The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion proliferation (TLP) determined by FDG and 3'-deoxy-3'-F-fluorothymidine (FLT) PET for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib.

PATIENTS AND METHODS

FDG-PET and FLT-PET were performed in 30 patients with untreated Stage IV NSCLC before start of therapy, 1 (early) and 6 (late) weeks after erlotinib treatment. Functional tumor volume parameters including TLG in FDG-PET and TLP in FLT-PET were measured in the sum of up to 5 lesions per scan. Metabolic response was assessed using different cutoff values for percentage changes of TLG and TLP. Absolute baseline and residual levels of TLG and TLP were used for dichotomizing the patients into 2 groups. Kaplan-Meier analysis and the log-rank test were performed to analyze the association with progression-free survival (PFS).

RESULTS

Patients with a metabolic response measured by early changes of TLP and late changes of TLG and TLP showed a significantly better PFS than metabolically nonresponding patients. A lower cutoff value of 20% or 30% for definition of metabolic response showed better differentiation between metabolically responding and nonresponding patients in cases where the 45% cutoff value revealed no significant results. Furthermore, patients with lower absolute early and late residual TLG and TLP levels had a significantly prolonged PFS. In contrast, absolute baseline TLG and TLP levels showed no significant association with PFS.

CONCLUSIONS

In patients with advanced NSCLC, percentage changes of TLG and TLP and absolute residual TLG and TLP levels under erlotinib treatment emerged as strong predictive factors for PFS. Our findings indicate that a cutoff value of 20% or 30% for definition of metabolic response measured by percentage changes of TLG and TLP provides suitable results for response prediction, which should be further validated.

摘要

目的

评估氟脱氧葡萄糖(FDG)和 3'-去氧-3'-F-氟代胸苷(FLT)PET 测定的肿瘤病变糖酵解(TLG)和肿瘤病变增殖(TLP)在接受厄洛替尼治疗的晚期非小细胞肺癌(NSCLC)患者中的预测价值和预后差异。

患者和方法

在开始治疗前,对 30 名未经治疗的 IV 期 NSCLC 患者进行 FDG-PET 和 FLT-PET 检查,治疗后 1(早期)和 6(晚期)周进行检查。在每次扫描的最多 5 个病变中测量包括 FDG-PET 中的 TLG 和 FLT-PET 中的 TLP 在内的功能肿瘤体积参数。使用 TLG 和 TLP 百分比变化的不同截止值评估代谢反应。使用 TLG 和 TLP 的绝对基线和残留水平将患者分为 2 组。进行 Kaplan-Meier 分析和对数秩检验以分析与无进展生存期(PFS)的相关性。

结果

通过早期 TLP 变化和晚期 TLG 和 TLP 变化测量的代谢反应患者的 PFS 明显优于代谢无反应患者。较低的 20%或 30%的截止值用于定义代谢反应,当 45%的截止值没有显示出显著结果时,在代谢反应和无反应患者之间的差异有更好的区分。此外,早期和晚期残留 TLG 和 TLP 水平较低的患者 PFS 明显延长。相比之下,绝对基线 TLG 和 TLP 水平与 PFS 无显著关联。

结论

在晚期 NSCLC 患者中,TLG 和 TLP 的百分比变化以及厄洛替尼治疗下的 TLG 和 TLP 的绝对残留水平是 PFS 的强烈预测因素。我们的研究结果表明,使用 TLG 和 TLP 的百分比变化定义代谢反应的 20%或 30%的截止值为反应预测提供了合适的结果,应进一步验证。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验